Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
The Efficacy, Safety and Genetic Polymorphism of Hypoca and Adalat OROS in Hypertensive Patients
This study has been completed.
Sponsored by: National Taiwan University Hospital
Information provided by: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT00728858
  Purpose

Nifedipine and barnidipine act as calcium channel blockers, and are widely prescribed for pressure control of prehypertension and stage 1 hypertension.

CYP3A4 is responsible for the metabolism of nifedipine and nifedipine, while the contribution of CYP3A5 remains ambiguous. This study is aimed to analyze the association between antihypertensive effects of nifedipine as well as barnidipine and single nucleotide polymorphisms of CYP3A4, CYP3A5 and calcium channels.


Condition
Hypertension

MedlinePlus related topics: High Blood Pressure
Drug Information available for: Nifedipine Barnidipine
U.S. FDA Resources
Study Type: Observational
Study Design: Case Control, Prospective
Official Title: An Open-Label, Randomized Clinical Study to Evaluate the Efficacy, Safety and Genetic Polymorphism of Hypoca(Barnidipine)and Adalat OROS(Nifedipine) in Mild to Moderate Hypertensive Patients

Further study details as provided by National Taiwan University Hospital:

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

Extract DNA from buffy coat. Test drug concentration in plasma.


Enrollment: 43
Study Start Date: April 2006
Study Completion Date: February 2007
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Detailed Description:

For each drug, 20 patients will be enrolled. Patients' blood pressure and heart rates will be measured at first visit, followed by visits at week4 , week 8 and week 12. Blood samples will be drawn at week 4 and week 12 for following analyses of drug plasma concentrations. SNPs in CYP3A4, CYP3A5 and calcium channel v 1.2 will be genotyped using SNPstream.

The differences in the decrease of blood pressures and the durg plasma concentrations between genotypes will be analyzed.

  Eligibility

Ages Eligible for Study:   22 Years to 87 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Hypertension patients living in Taiwan

Criteria

Inclusion Criteria:

  • 20~90 years old patient
  • mild to moderate hypertensive patients
  • can finish this study
  • can sign agreement

Exclusion Criteria:

  • severe hypertension
  • Heart failure, Arrhythmia
  • Liver or kidney failure
  • pregnant women
  • allergy to dihydropyridines
  • attend other clinical trials in past 3 month
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00728858

Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Study Chair: FU-TIEN CHIANG, Doctor National Taiwan University Hospital
  More Information

Responsible Party: National Taiwan University Hospital ( National Taiwan University Hospital )
Study ID Numbers: 941227
Study First Received: May 28, 2008
Last Updated: August 1, 2008
ClinicalTrials.gov Identifier: NCT00728858  
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
Hypertension
SNP
Nifedipine
Barnidipine

Study placed in the following topic categories:
Vascular Diseases
Nifedipine
Hypertension

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 13, 2009



U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services